Posted: 17 March 2026
MTPConnect has announced the seven Victorian medtech companies selected to participate in the 2026 Pathway to Market – Medtech Capability Uplift Program, an initiative designed to strengthen the readiness of Australian medical technology innovators to engage with local health procurement systems.
The selected companies have been addressing critical healthcare needs across areas including infection prevention, chronic disease management, artificial intelligence-enabled patient monitoring, medication safety and advanced diagnostic technologies. Through the programme, participating small and medium-sized enterprises (SMEs) have been supported to better understand hospital procurement processes and prepare their products for adoption within the healthcare system.
Speaking at the programme’s launch event, MTPConnect Chief Executive Officer Stuart Dignam said the initiative had been created to help Australian-developed medical technologies reach hospitals and health services more effectively.
“For many medtech SMEs, entering the local health market remains complex and resource intensive. We also know that being ‘procurement ready’ requires more than just a strong product,” Mr Dignam said.
The announcement was made during MTPConnect’s Medtech Selling to Health Masterclass, where senior hospital clinicians, procurement leaders and health system stakeholders had gathered to provide practical guidance on procurement challenges and pathways for emerging medtech companies.
Mr Dignam noted that the programme had been delivered for a second year following strong industry interest.
“This is the second year we have rolled out our sought-after Pathway to Market Program which provides capability assessments, tailored practical workshops and expert insights to help SMEs get ready to navigate the Victorian Government’s procurement pathway,” he said.
Victoria has served as the pilot jurisdiction for the programme, with support from the Victorian Government. According to Mr Dignam, the initiative has been designed to establish the foundations for a broader national effort aimed at strengthening medtech innovation and manufacturing.
The companies selected for the 2026 Pathway to Market cohort include 4D Medical, Arelis, Lenexa Medical, Mediklean, MX3 Diagnostics, Proton Intelligence Australia and Sadleir Laboratories, each developing technologies targeting key clinical and healthcare system challenges.
The program forms part of the Australian Medtech Manufacturing Alliance (AMMA) and has been delivered by MTPConnect in partnership with BioMelbourne Network, with support from the Victorian Government. The Masterclass event has been hosted by Velos Accelerator at the Victorian Heart Hospital within the Monash Technology Precinct.
